Blunt cerebrovascular injuries (BCVI) involve trauma to the carotid or vertebral arteries and carry a high risk of debilitating strokes if left untreated. Historically viewed as rare, these injuries are now identified in up to 3% of blunt trauma cases through aggressive screening of high-risk patients using computed tomographic angiography. Most patients experience an asymptomatic latent period, providing a critical therapeutic window to intervene before neurological damage occurs. Treatment primarily utilizes antithrombotic medications, such as heparin or aspirin, which have significantly lowered mortality and stroke rates. While the Denver Grading Scale helps clinicians assess injury severity and stroke risk, surgical or endovascular interventions like stenting remain reserved for rare, complex cases. Ultimately, early detection during the "silent period" is the most effective strategy for preventing permanent disability or death.

DISCLAIMER

This study guide provides an exhaustive synthesis of the screening, grading, and management of blunt cerebrovascular injuries (BCVIs), based on contemporary medical research and clinical protocols.

Blunt cerebrovascular injuries, which encompass trauma to the carotid and vertebral arteries, were historically associated with devastating and unavoidable neurologic outcomes. In the early 1990s, the perception of these injuries shifted as reports suggested that anticoagulation could improve outcomes for patients suffering ischemic neurologic events (INEs).

Research over the past three decades has established a scientific rationale for early screening and preemptive antithrombotic management. If left untreated, the risks are significant: carotid artery injuries (CAIs) carry a stroke rate of up to 50% depending on the grade, while vertebral artery injuries (VAIs) have a stroke rate between 20% and 25%. Modern screening protocols aim to identify these injuries in asymptomatic patients during a "silent period" to prevent neurologic sequelae. Consequently, BCVI-related mortality has dropped from 24% in the 1980s to less than 5% today.

The symptoms of BCVI are determined by the distribution of the lesion, the presence of underlying cerebrovascular disease, and the completeness of the Circle of Willis, which is incomplete in 80% of the population.

VAIs often present with more vague symptoms, including:

Prompt investigation is required if any of the following are present:

The majority of BCVI patients exhibit a "latent period" or "silent period" between the initial injury and the onset of stroke symptoms. While this phase can range from hours to years, most symptoms develop within 12 to 75 hours post-injury. Diagnosing BCVI during this asymptomatic window is the primary goal of screening, as it allows for treatment that can effectively prevent a stroke.

There are three fundamental mechanisms that result in BCVI:

Regardless of the mechanism, the result is often an intimal tear. This tear exposes subendothelial collagen, creating a site (nidus) for platelet aggregation, which may lead to thrombosis, emboli, pseudoaneurysm formation, or vessel occlusion.

Modern screening extends beyond symptomatic patients to include those with high-risk injury patterns.

Historically the "gold standard," DSA is now less common for initial screening because it is invasive, costly, and carries risks of embolic complications. It remains necessary when clinical suspicion is high despite negative noninvasive tests or to confirm findings to avoid unnecessary anticoagulation.

CTA is the preferred screening tool because it is noninvasive and widely available. While early-generation CTAs had low sensitivity, modern multidetector-row CTA (16- to 64-slice) has significantly improved accuracy.

Injuries are categorized by severity to determine stroke risk and treatment.

Indeterminate BCVI: Includes stretch injuries or questionable dissections that do not meet classic grading. Since 25% of these progress to true BCVI, they are typically treated as such.

Antithrombotic agents are the mainstay of treatment and should be initiated as soon as possible, ideally within the first 24 hours when stroke risk peaks.

Patients are typically reimaged 7 to 10 days after diagnosis.

Despite modern treatments, the impact of BCVI-related stroke remains high. Permanent severe neurologic disability occurs in 48% to 58% of CAI-related stroke survivors. Furthermore, those who suffer an INE have significantly higher mortality rates (32% for CAI and 18% for VAI) compared to those who do not (7% for both).

--------------------------------------------------------------------------------